2025 Q4 -tulosraportti
Vain PDF
129 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 min sitten · MuokattuHeart, CNS/central nervous system/brain, eye, muscles, lungs, kidneys, autoimmune diseases, cancer, cell therapies, vaccines - projects with circVec are now underway worldwide, USA, Europe, Asia, Canada. The activity is massive and much is being done and paid for by partners who see the potential in the technology to combine it with their own projects and their own technology. It is in the process of becoming an international technology. On August 31st, they have announced new results and Lubor van Gaal strongly recommended paying attention to the H1 presentation.
·36 min sittenTHE COLLABORATIONS ROLLING RIGHT NOW 🤝🧬 🏋️ Top-5 pharma — CNS, in vivo phase. They pay themselves. 🧬 Acuitas — LNP delivery to T-cells, in vivo CAR-T 🇩🇪 Tcelltech — nanoSMAR-vector, next generation CAR-T/TCR-T 🎯 GenAssist — circVec-enhanced AAV capsids for low-dose systemic 🤖 Avenue Biosciences — AI-designed protein secretion 🦠 United Immunity — in vivo CAR-Macrophage Plus several research collaborations mentioned in the investor presentation — AaviGen, TraffikGene, Certest, UTMB. Do you see the breadth? 👀 Different delivery methods. Different organs. Different modalities. All built on the same engine: circVec. Each collaboration tests the platform in a new dimension — and the partners bear the cost. Non-dilutive validation, time and again. 💰 One partner is a coincidence. Six confirmed are a pattern. 🧱 We know what we own. ♟️🍷- ·1 t sittenTHE POSITIVE — OVERALL, AND WITHOUT EMBELLISHMENT. 🧬 The field is the hottest in modern medicine. RNA therapy generated over 7 bn USD in 2025, with 734 ongoing clinical studies and over 17 bn USD in licensing agreements the same year. circRNA is described by the industry as the first wave beyond mRNA. This is not a niche — it is the direction the entire field is going. 🌍 The technology is truly differentiated. Even the most thorough critical analysis called the differentiation «largely uncontested». All the big players use synthetic circRNA in LNP. Circio encodes it in a vector so the cell builds the ring itself. Its own path. 🔵 The mechanism is properly controlled. The vector copy number was not significantly different between the groups — while the RNA quantity was, by an enormous margin. This rules out that circVec «just delivers better». The effect is real. 🔬 Big pharma pays out of its own pocket. A top-5 player finances the feasibility study itself and took it further from in vitro to in vivo. Upon success, the stated intention is a licensing agreement. 🤝 The problem they are attacking is truly deadly. Rocket received a clinical hold after a death related to a high AAV dose. «Same effect at a fraction of the dose» is not a sales phrase — it is the difference between a therapy that can be used and one that cannot. 🫀 The people are the inventors. Wiklund and Hansen are behind the research that founded the field. Wiklund himself has told that Flagship — the people behind Moderna — started Laronde with 500 mill. USD based on their original discovery. Add Levitsky (Roche, Servier) and Dinah Sah, who led the RNAi programs behind the world's first approved RNAi medicine. 👑 What the market pays for such things: Lilly acquired Kelonia for up to 7 bn USD. BMS acquired Orbital for 1.5 bn. Lilly acquired Orna for 2.4 bn. All preclinical. No treated patients. 💸 The financing is secured. Runway until 2030, in a market where a third of listed biotech had less than one year of cash at year-end. They negotiate from a position of strength. 🔩 Several independent tracks. Heart, eye, CNS, in vivo CAR-T, secretion. One can disappoint without the platform dying. 🎯 And the catalysts are coming now. Four readouts in 2H plus ESGCT in Hamburg. Even the skeptics call them the most important near-term events. That's the case. Not proven yet — but that's why it's still early. 🧱 We know what we own. ♟️🍷
·2 t sittenWith approx. 620 million NOK raised in 1H 2026 and runway towards 2030, the company is in a completely different negotiating position than before. This reduces the risk that they have to give away broad circVec rights cheaply just to get money in the door, and I am particularly interested in the Big Pharma track. The current feasibility agreement gives no downstream rights. If the in vivo data hits and the partner wants to proceed, they actually have to pay for it. The most shareholder-friendly agreement is unlikely to be selling the entire platform, but a limited license per indication, target or delivery area — with upfront, milestones, royalties and partner-funded development. In short: The capital gives Circio time. And in biotech, time is often negotiating power.
Never encountered such an exciting stock ever, surely several others think this like me. Just hope this works out. Have followed this one for quite a while now. I think I've caught up on most of it. But there's always a 'but'. I believe this can work out, that's why I'm still holding a fairly decent position here. Looking forward to what's next here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
129 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 min sitten · MuokattuHeart, CNS/central nervous system/brain, eye, muscles, lungs, kidneys, autoimmune diseases, cancer, cell therapies, vaccines - projects with circVec are now underway worldwide, USA, Europe, Asia, Canada. The activity is massive and much is being done and paid for by partners who see the potential in the technology to combine it with their own projects and their own technology. It is in the process of becoming an international technology. On August 31st, they have announced new results and Lubor van Gaal strongly recommended paying attention to the H1 presentation.
- ·36 min sittenTHE COLLABORATIONS ROLLING RIGHT NOW 🤝🧬 🏋️ Top-5 pharma — CNS, in vivo phase. They pay themselves. 🧬 Acuitas — LNP delivery to T-cells, in vivo CAR-T 🇩🇪 Tcelltech — nanoSMAR-vector, next generation CAR-T/TCR-T 🎯 GenAssist — circVec-enhanced AAV capsids for low-dose systemic 🤖 Avenue Biosciences — AI-designed protein secretion 🦠 United Immunity — in vivo CAR-Macrophage Plus several research collaborations mentioned in the investor presentation — AaviGen, TraffikGene, Certest, UTMB. Do you see the breadth? 👀 Different delivery methods. Different organs. Different modalities. All built on the same engine: circVec. Each collaboration tests the platform in a new dimension — and the partners bear the cost. Non-dilutive validation, time and again. 💰 One partner is a coincidence. Six confirmed are a pattern. 🧱 We know what we own. ♟️🍷
- ·1 t sittenTHE POSITIVE — OVERALL, AND WITHOUT EMBELLISHMENT. 🧬 The field is the hottest in modern medicine. RNA therapy generated over 7 bn USD in 2025, with 734 ongoing clinical studies and over 17 bn USD in licensing agreements the same year. circRNA is described by the industry as the first wave beyond mRNA. This is not a niche — it is the direction the entire field is going. 🌍 The technology is truly differentiated. Even the most thorough critical analysis called the differentiation «largely uncontested». All the big players use synthetic circRNA in LNP. Circio encodes it in a vector so the cell builds the ring itself. Its own path. 🔵 The mechanism is properly controlled. The vector copy number was not significantly different between the groups — while the RNA quantity was, by an enormous margin. This rules out that circVec «just delivers better». The effect is real. 🔬 Big pharma pays out of its own pocket. A top-5 player finances the feasibility study itself and took it further from in vitro to in vivo. Upon success, the stated intention is a licensing agreement. 🤝 The problem they are attacking is truly deadly. Rocket received a clinical hold after a death related to a high AAV dose. «Same effect at a fraction of the dose» is not a sales phrase — it is the difference between a therapy that can be used and one that cannot. 🫀 The people are the inventors. Wiklund and Hansen are behind the research that founded the field. Wiklund himself has told that Flagship — the people behind Moderna — started Laronde with 500 mill. USD based on their original discovery. Add Levitsky (Roche, Servier) and Dinah Sah, who led the RNAi programs behind the world's first approved RNAi medicine. 👑 What the market pays for such things: Lilly acquired Kelonia for up to 7 bn USD. BMS acquired Orbital for 1.5 bn. Lilly acquired Orna for 2.4 bn. All preclinical. No treated patients. 💸 The financing is secured. Runway until 2030, in a market where a third of listed biotech had less than one year of cash at year-end. They negotiate from a position of strength. 🔩 Several independent tracks. Heart, eye, CNS, in vivo CAR-T, secretion. One can disappoint without the platform dying. 🎯 And the catalysts are coming now. Four readouts in 2H plus ESGCT in Hamburg. Even the skeptics call them the most important near-term events. That's the case. Not proven yet — but that's why it's still early. 🧱 We know what we own. ♟️🍷
- ·2 t sittenWith approx. 620 million NOK raised in 1H 2026 and runway towards 2030, the company is in a completely different negotiating position than before. This reduces the risk that they have to give away broad circVec rights cheaply just to get money in the door, and I am particularly interested in the Big Pharma track. The current feasibility agreement gives no downstream rights. If the in vivo data hits and the partner wants to proceed, they actually have to pay for it. The most shareholder-friendly agreement is unlikely to be selling the entire platform, but a limited license per indication, target or delivery area — with upfront, milestones, royalties and partner-funded development. In short: The capital gives Circio time. And in biotech, time is often negotiating power.Never encountered such an exciting stock ever, surely several others think this like me. Just hope this works out. Have followed this one for quite a while now. I think I've caught up on most of it. But there's always a 'but'. I believe this can work out, that's why I'm still holding a fairly decent position here. Looking forward to what's next here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
129 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 min sitten · MuokattuHeart, CNS/central nervous system/brain, eye, muscles, lungs, kidneys, autoimmune diseases, cancer, cell therapies, vaccines - projects with circVec are now underway worldwide, USA, Europe, Asia, Canada. The activity is massive and much is being done and paid for by partners who see the potential in the technology to combine it with their own projects and their own technology. It is in the process of becoming an international technology. On August 31st, they have announced new results and Lubor van Gaal strongly recommended paying attention to the H1 presentation.
- ·36 min sittenTHE COLLABORATIONS ROLLING RIGHT NOW 🤝🧬 🏋️ Top-5 pharma — CNS, in vivo phase. They pay themselves. 🧬 Acuitas — LNP delivery to T-cells, in vivo CAR-T 🇩🇪 Tcelltech — nanoSMAR-vector, next generation CAR-T/TCR-T 🎯 GenAssist — circVec-enhanced AAV capsids for low-dose systemic 🤖 Avenue Biosciences — AI-designed protein secretion 🦠 United Immunity — in vivo CAR-Macrophage Plus several research collaborations mentioned in the investor presentation — AaviGen, TraffikGene, Certest, UTMB. Do you see the breadth? 👀 Different delivery methods. Different organs. Different modalities. All built on the same engine: circVec. Each collaboration tests the platform in a new dimension — and the partners bear the cost. Non-dilutive validation, time and again. 💰 One partner is a coincidence. Six confirmed are a pattern. 🧱 We know what we own. ♟️🍷
- ·1 t sittenTHE POSITIVE — OVERALL, AND WITHOUT EMBELLISHMENT. 🧬 The field is the hottest in modern medicine. RNA therapy generated over 7 bn USD in 2025, with 734 ongoing clinical studies and over 17 bn USD in licensing agreements the same year. circRNA is described by the industry as the first wave beyond mRNA. This is not a niche — it is the direction the entire field is going. 🌍 The technology is truly differentiated. Even the most thorough critical analysis called the differentiation «largely uncontested». All the big players use synthetic circRNA in LNP. Circio encodes it in a vector so the cell builds the ring itself. Its own path. 🔵 The mechanism is properly controlled. The vector copy number was not significantly different between the groups — while the RNA quantity was, by an enormous margin. This rules out that circVec «just delivers better». The effect is real. 🔬 Big pharma pays out of its own pocket. A top-5 player finances the feasibility study itself and took it further from in vitro to in vivo. Upon success, the stated intention is a licensing agreement. 🤝 The problem they are attacking is truly deadly. Rocket received a clinical hold after a death related to a high AAV dose. «Same effect at a fraction of the dose» is not a sales phrase — it is the difference between a therapy that can be used and one that cannot. 🫀 The people are the inventors. Wiklund and Hansen are behind the research that founded the field. Wiklund himself has told that Flagship — the people behind Moderna — started Laronde with 500 mill. USD based on their original discovery. Add Levitsky (Roche, Servier) and Dinah Sah, who led the RNAi programs behind the world's first approved RNAi medicine. 👑 What the market pays for such things: Lilly acquired Kelonia for up to 7 bn USD. BMS acquired Orbital for 1.5 bn. Lilly acquired Orna for 2.4 bn. All preclinical. No treated patients. 💸 The financing is secured. Runway until 2030, in a market where a third of listed biotech had less than one year of cash at year-end. They negotiate from a position of strength. 🔩 Several independent tracks. Heart, eye, CNS, in vivo CAR-T, secretion. One can disappoint without the platform dying. 🎯 And the catalysts are coming now. Four readouts in 2H plus ESGCT in Hamburg. Even the skeptics call them the most important near-term events. That's the case. Not proven yet — but that's why it's still early. 🧱 We know what we own. ♟️🍷
- ·2 t sittenWith approx. 620 million NOK raised in 1H 2026 and runway towards 2030, the company is in a completely different negotiating position than before. This reduces the risk that they have to give away broad circVec rights cheaply just to get money in the door, and I am particularly interested in the Big Pharma track. The current feasibility agreement gives no downstream rights. If the in vivo data hits and the partner wants to proceed, they actually have to pay for it. The most shareholder-friendly agreement is unlikely to be selling the entire platform, but a limited license per indication, target or delivery area — with upfront, milestones, royalties and partner-funded development. In short: The capital gives Circio time. And in biotech, time is often negotiating power.Never encountered such an exciting stock ever, surely several others think this like me. Just hope this works out. Have followed this one for quite a while now. I think I've caught up on most of it. But there's always a 'but'. I believe this can work out, that's why I'm still holding a fairly decent position here. Looking forward to what's next here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt